LamdaGen and Arisan Receive $2 M NIH SBIR Phase II Grant to Advance Development of a Single, Rapid POC Assay for Detection of Acute Dengue and Zika Viral Infections
Menlo Park, CA and San Diego, CA – LamdaGen Corporation and Arisan Therapeutics announced today they have been awarded a $2 million Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases, a Continue reading